jueves, 12 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow?

View original at nasdaq.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? Key Points The company had a fine second quarter, and investors will be hoping for a repeat…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Starbucks attributed its solid second-quarter performance to the Back to Starbucks initiative

    60% confidence

  • Analysts collectively expect Starbucks to post just over $9.1 billion in revenue and $0.65 per share in net income for fiscal Q3 2026 — nearly 4% below the prior-year revenue figure but a 30% improvement in EPS year over year

    60% confidence

  • Starbucks is a mature business with a huge footprint that has little room to grow, and its stock is priced for hot growth with a forward P/E of almost 35 that profitability gains are unlikely to match; even a beat on Q3 earnings would not change this negative view

    60% confidence

  • Full-year 2026 comparable sales guidance raised to at least 5% growth (from more than 3% previously), and adjusted EPS guidance raised to $2.25-$2.45 (from $2.15-$2.40 previously)

    60% confidence

Data points we hold from this source

Starbucks Corporation · forward pe35 ratio
Starbucks Corporation · stock price23 percent_ytd_change
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? — Source | Via News | es.VIA.NEWS